Title:The Role of GATA3 in Breast Cancer: An Updated Review
Volume: 1
Issue: 6
Author(s): Jing Yang, Xu Zhao, Ruoyu Huang, Juanjuan Zhao, Mengmeng Guo, Ya Zhou*Lin Xu*
Affiliation:
- Special Key Laboratory of Gene Detection and Therapy & Base for Talents of Biotherapy of Guizhou Province, Zunyi 563000,China
- Special Key Laboratory of Gene Detection and Therapy & Base for Talents of Biotherapy of Guizhou Province, Zunyi 563000,China
Keywords:
GATA binding protein 3, breast cancer, microRNA, transcription factor, GATA3, transcriptional binding.
Abstract: GATA binding protein 3 (GATA3), a member of the zinc finger-binding transcription
factor GATA gene family, plays an important role in regulating the development and differentiation
of various tissues and organs. Previous studies have manifested that GATA3 is implicated in inhibiting
the development of breast cancer, including suppressing the growth, metastasis, and invasion of
cancer cells. However, the exact role of GATA3 in breast cancer remains to be fully elucidated. Interestingly,
recent studies have further shown that GATA3 can regulate a variety of new target
genes, including ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3), semaphorin 3B
(SEMA3B), and microRNAs (miRNAs) to promote tumorigenesis, epithelial-mesenchymal transformation
(EMT), and metastasis of breast cancer. Meanwhile, GATA3 mutations can affect the role
of GATA3 in inhibiting the growth and metastasis of breast cancer cells, which indicates that GATA3
might be a promising target for breast cancer treatment. Undoubtedly, these new evidence further
uncover the complexity of the GATA3/targets network in breast cancer development. In this
article, we review related research progress and put forward some questions about the development
of GATA3 in the future in order to be helpful for the understanding on the exact role of GATA3 in
the progress of breast cancer and the development of related new clinical treatment strategies that
will ultimately benefit the clinical outcome of breast cancer patients.
